CY1113071T1 - Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα - Google Patents

Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα

Info

Publication number
CY1113071T1
CY1113071T1 CY20121100765T CY121100765T CY1113071T1 CY 1113071 T1 CY1113071 T1 CY 1113071T1 CY 20121100765 T CY20121100765 T CY 20121100765T CY 121100765 T CY121100765 T CY 121100765T CY 1113071 T1 CY1113071 T1 CY 1113071T1
Authority
CY
Cyprus
Prior art keywords
optional
competitor
kappa
competitive
schizophrenia
Prior art date
Application number
CY20121100765T
Other languages
English (en)
Inventor
Buezo Nuria Diaz
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113071T1 publication Critical patent/CY1113071T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Ένας επιλεκτικός ανταγωνιστής κάππα οπιοειδούς υποδοχέα που έχει τον τύπο (Ι) χρήσιμος για την αγωγή της απεξάρτησης από την διαταραχή της χρήσης αιθανόλης και του άγχους, και/ή της κατάθλιψης, ή της σχιζοφρένειας ως ανεξάρτητων καταστάσεων συννοσηρότητας.
CY20121100765T 2008-01-22 2012-08-24 Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα CY1113071T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25
EP09703808A EP2252581B1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (1)

Publication Number Publication Date
CY1113071T1 true CY1113071T1 (el) 2016-04-13

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100765T CY1113071T1 (el) 2008-01-22 2012-08-24 Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα

Country Status (33)

Country Link
US (2) US7709522B2 (el)
EP (1) EP2252581B1 (el)
JP (1) JP5345637B2 (el)
KR (1) KR101172170B1 (el)
CN (1) CN101925576B (el)
AR (1) AR070158A1 (el)
AU (1) AU2009206653B2 (el)
BR (1) BRPI0907382B8 (el)
CA (1) CA2713025C (el)
CO (1) CO6290644A2 (el)
CY (1) CY1113071T1 (el)
DK (1) DK2252581T3 (el)
DO (1) DOP2010000222A (el)
EA (1) EA017484B1 (el)
EC (1) ECSP10010365A (el)
ES (1) ES2388708T3 (el)
HK (1) HK1146822A1 (el)
HR (1) HRP20120558T1 (el)
IL (1) IL206038A (el)
JO (1) JO2797B1 (el)
MA (1) MA32751B1 (el)
MX (1) MX2010007849A (el)
MY (1) MY163014A (el)
NZ (1) NZ586225A (el)
PE (1) PE20091317A1 (el)
PL (1) PL2252581T3 (el)
PT (1) PT2252581E (el)
SI (1) SI2252581T1 (el)
TN (1) TN2010000306A1 (el)
TW (1) TWI422369B (el)
UA (1) UA100715C2 (el)
WO (1) WO2009094260A1 (el)
ZA (1) ZA201003908B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20125637B (en) * 2008-01-22 2012-09-10 Takeda Pharmaceutical Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
JP5345637B2 (ja) * 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
WO2013086496A2 (en) 2011-12-09 2013-06-13 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
WO2014190270A1 (en) * 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US10676469B2 (en) 2017-03-17 2020-06-09 Blackthorn Therapeutics, Inc. Kappa opioid receptor antagonists and products and methods related thereto
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3219079A1 (en) 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
WO2023131920A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023131921A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170547A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
TW202345796A (zh) 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式
WO2023170554A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) * 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
US20020052365A1 (en) * 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
JP2005525392A (ja) * 2002-03-28 2005-08-25 ウィシス テクノロジー ファウンデーション，インコーポレイティド 減少された鎮静及び失調効果を有する抗不安薬剤
EP1562595B1 (en) 2002-09-19 2008-05-21 Eli Lilly And Company Diaryl ethers as opioid receptor antagonists
US7396943B2 (en) 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
ES2294475T3 (es) 2003-03-07 2008-04-01 Eli Lilly And Company Derivados de nicotinamida g-sustituidos como antagonistas de receptores de opioides.
ES2456705T3 (es) 2003-12-12 2014-04-23 Eli Lilly & Company Antagonistas de receptores opioides
BRPI0417714A (pt) 2003-12-22 2007-03-20 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
CA2558568A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
WO2005090337A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
AU2007236003B2 (en) 2006-04-04 2012-10-18 Emodys Gmbh Use of kappa opioid receptor antagonist-containing compositions for the treatment of dissociative disorders
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008021849A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
JP5345637B2 (ja) * 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト

Also Published As

Publication number Publication date
CA2713025C (en) 2012-12-04
SI2252581T1 (sl) 2012-09-28
US20090186873A1 (en) 2009-07-23
IL206038A (en) 2013-11-28
JO2797B1 (en) 2014-03-15
PT2252581E (pt) 2012-08-31
ZA201003908B (en) 2011-11-30
DOP2010000222A (es) 2015-11-15
EP2252581B1 (en) 2012-06-20
DK2252581T3 (da) 2012-07-16
EA201070877A1 (ru) 2010-12-30
PE20091317A1 (es) 2009-09-03
HK1146822A1 (en) 2011-07-15
MY163014A (en) 2017-07-31
BRPI0907382B1 (pt) 2020-03-10
PL2252581T3 (pl) 2012-10-31
KR20100095639A (ko) 2010-08-31
KR101172170B1 (ko) 2012-08-07
ES2388708T3 (es) 2012-10-17
AR070158A1 (es) 2010-03-17
US7709522B2 (en) 2010-05-04
AU2009206653B2 (en) 2013-07-18
US8173695B2 (en) 2012-05-08
EP2252581A1 (en) 2010-11-24
CA2713025A1 (en) 2009-07-30
WO2009094260A1 (en) 2009-07-30
US20100197669A1 (en) 2010-08-05
JP5345637B2 (ja) 2013-11-20
CN101925576A (zh) 2010-12-22
CN101925576B (zh) 2013-02-06
MX2010007849A (es) 2010-08-09
CO6290644A2 (es) 2011-06-20
BRPI0907382B8 (pt) 2021-05-25
IL206038A0 (en) 2010-11-30
UA100715C2 (ru) 2013-01-25
NZ586225A (en) 2012-05-25
TW200936129A (en) 2009-09-01
TN2010000306A1 (en) 2011-11-11
MA32751B1 (fr) 2011-11-01
ECSP10010365A (es) 2010-08-31
AU2009206653A1 (en) 2009-07-30
JP2011524850A (ja) 2011-09-08
TWI422369B (zh) 2014-01-11
EA017484B1 (ru) 2012-12-28
BRPI0907382A2 (pt) 2015-07-21
HRP20120558T1 (hr) 2012-10-31

Similar Documents

Publication Publication Date Title
CY1113071T1 (el) Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα
CY1119102T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεισαυτων
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
MA32547B1 (fr) Antagonistes specifiques du recepteur fgf-r4
ATE469895T1 (de) Cgrp-rezeptorantagonisten
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE471940T1 (de) Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
BRPI0922384A2 (pt) "manipulador de suprimento para equipamento".
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
ATE526325T1 (de) Substituierte benzimidazole als kinaseinhibitoren
IT1392499B1 (it) Dispositivo di rilevamento dell'impatto.
EA201170227A1 (ru) Имидазолкарбоксамиды
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
UY32331A (es) Compuestos novedosos como ligandos de receptores de canabinoides
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
BRPI0923237A2 (pt) compostos de 4-azetidinil-1-heteroaril-ciclohexanol antagonistas de ccr2
CO6260091A2 (es) Derivados de iminopiridina y su uso
UA107684C2 (xx) АГОНІСТИ РЕЦЕПТОРА mGlu2
FR2931365B3 (fr) Dispositif d'entrainement.
CL2008001795A1 (es) Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.
UY33225A (es) (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4
CO6251376A2 (es) Triazolilpiridina cetonas herbicidas